X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761079
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761079
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761079
https://www.prnewswire.com/news-releases/biomarin-pioneer-in-rare-disease-treatments-for-phenylketonuria-pku-receives-fda-approval-of-label-expansion-to-allow-maximum-dose-of-60-mg-for-palynziq-pegvaliase-pqpz-injection-for-treatment-of-adults-with-pku-301147358.html
http://www.pmlive.com/pharma_news/eu_nod_for_biomarins_second_pku_therapy_palynziq_1286947
http://www.news.sanofi.us/2019-05-07-Dupixent-R-dupilumab-Approved-for-Severe-Asthma-by-European-Commission
http://www.pmlive.com/pharma_news/eu_nod_for_biomarins_second_pku_therapy_palynziq_1286947
https://www.prnewswire.com/news-releases/european-commission-approves-palynziq-pegvaliase-injection-for-treatment-of-phenylketonuria-pku-in-patients-aged-16-years-or-older-300844276.html
https://www.prnewswire.com/news-releases/biomarin-receives-positive-chmp-opinion-in-europe-for-palynziq-pegvaliase-injection-for-treatment-of-patients-with-phenylketonuria-pku-aged-16-and-older-300804918.html
https://www.drugdevelopment-technology.com/projects/palynziq-pegvaliase-pqpz-for-the-treatment-of-adults-with-phenylketonuria/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761079
https://www.fiercepharma.com/pharma/biomarin-scores-long-sought-fda-nod-for-rare-disease-drug-but-can-it-hit-blockbuster-status
Market Place
Share 
